Search

Your search keyword '"Cohen, A.D."' showing total 218 results
Start Over Author "Cohen, A.D."
218 results on '"Cohen, A.D."'

1. Analyse intégrée, issue de 26 études cliniques, des infections fongiques apparues sous traitement chez les patients atteints de psoriasis, de rhumatisme psoriasique ou de spondyloarthrite axiale traités par ixékizumab

Author

Schwartzman, S., primary, Puig, L., additional, Cohen, A.D., additional, Khattri, S., additional, Jossart, C., additional, Diaz, C., additional, Garrelts, A., additional, Zhu, D., additional, Eberhart, N., additional, Eleftheriadi, A., additional, Tangsirisap, N., additional, Schuster, C., additional, Gottlieb, A.B., additional, and Goupille, P., additional

Published
2023
Full Text
View/download PDF

2. P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

Author

van de Donk, N., primary, Mateos, M.-V., additional, Cohen, Y.C., additional, Rodriguez-Otero, P., additional, Paiva, B., additional, Cohen, A.D., additional, Martin, T., additional, Suvannasankha, A., additional, Madduri, D., additional, Corsale, C., additional, Schecter, J.M., additional, De Braganca, K.C., additional, Jackson, C.C., additional, Varsos, H., additional, Deraedt, W., additional, Roccia, T., additional, Mistry, P., additional, Xu, X., additional, Li, K., additional, Zudaire, E., additional, Akram, M., additional, Pacaud, L., additional, Avivi, I., additional, and San-Miguel, J., additional

Published
2023
Full Text
View/download PDF

3. B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

Author

Zweegman, S., primary, Agha, M., additional, Cohen, A.D., additional, Cohen, Y.C., additional, Anguille, S., additional, Kerre, T., additional, Roeloffzen, W., additional, Madduri, D., additional, Schecter, J.M., additional, De Braganca, K.C., additional, Jackson, C.C., additional, Varsos, H., additional, Mistry, P., additional, Roccia, T., additional, Xu, X., additional, Li, K., additional, Zudaire, E., additional, Corsale, C., additional, Akram, M., additional, Geng, D., additional, Pacaud, L., additional, Sonneveld, P., additional, and van de Donk, N., additional

Published
2023
Full Text
View/download PDF

7. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Author

Raje, N.S. Anaissie, E. Kumar, S.K. Lonial, S. Martin, T. Gertz, M.A. Krishnan, A. Hari, P. Ludwig, H. O'Donnell, E. Yee, A. Kaufman, J.L. Cohen, A.D. Garderet, L. Wechalekar, A.F. Terpos, E. Khatry, N. Niesvizky, R. Yi, Q. Joshua, D.E. Saikia, T. Leung, N. Engelhardt, M. Mothy, M. Branagan, A. Chari, A. Reiman, A.J. Lipe, B. Richter, J. Rajkumar, S.V. Miguel, J.S. Anderson, K.C. Stadtmauer, E.A. Prabhala, R.H. McCarthy, P.L. Munshi, N.C.

Abstract

Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications. © 2022 Elsevier Ltd

Published
2022

21. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need

Author

Babulal, G.M. Quiroz, Y.T. Albensi, B.C. Arenaza-Urquijo, E. Astell, A.J. Babiloni, C. Bahar-Fuchs, A. Bell, J. Bowman, G.L. Brickman, A.M. Chételat, G. Ciro, C. Cohen, A.D. Dilworth-Anderson, P. Dodge, H.H. Dreux, S. Edland, S. Esbensen, A. Evered, L. Ewers, M. Fargo, K.N. Fortea, J. Gonzalez, H. Gustafson, D.R. Head, E. Hendrix, J.A. Hofer, S.M. Johnson, L.A. Jutten, R. Kilborn, K. Lanctôt, K.L. Manly, J.J. Martins, R.N. Mielke, M.M. Morris, M.C. Murray, M.E. Oh, E.S. Parra, M.A. Rissman, R.A. Roe, C.M. Santos, O.A. Scarmeas, N. Schneider, L.S. Schupf, N. Sikkes, S. Snyder, H.M. Sohrabi, H.R. Stern, Y. Strydom, A. Tang, Y. Terrera, G.M. Teunissen, C. Melo van Lent, D. Weinborn, M. Wesselman, L. Wilcock, D.M. Zetterberg, H. O'Bryant, S.E. International Society to Advance Alzheimer's Research Treatment, Alzheimer's Association

Abstract

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise “state-of-the-science” report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations. © 2018 The Authors

Published
2019

22. Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia

Author

Jansen, W.J. Ossenkoppele, R. Tijms, B.M. Fagan, A.M. Hansson, O. Klunk, W.E. Van Der Flier, W.M. Villemagne, V.L. Frisoni, G.B. Fleisher, A.S. Lleó, A. Mintun, M.A. Wallin, A. Engelborghs, S. Na, D.L. Chételat, G. Molinuevo, J.L. Landau, S.M. Mattsson, N. Kornhuber, J. Sabri, O. Rowe, C.C. Parnetti, L. Popp, J. Fladby, T. Jagust, W.J. Aalten, P. Lee, D.Y. Vandenberghe, R. De Oliveira, C.R. Kapaki, E. Froelich, L. Ivanoiu, A. Gabryelewicz, T. Verbeek, M.M. Sanchez-Juan, P. Hildebrandt, H. Camus, V. Zboch, M. Brooks, D.J. Drzezga, A. Rinne, J.O. Newberg, A. De Mendonça, A. Sarazin, M. Rabinovici, G.D. Madsen, K. Kramberger, M.G. Nordberg, A. Mok, V. Mroczko, B. Wolk, D.A. Meyer, P.T. Tsolaki, M. Scheltens, P. Verhey, F.R.J. Visser, P.J. Aarsland, D. Alcolea, D. Alexander, M. Almdahl, I.S. Arnold, S.E. Baldeiras, I. Barthel, H. Van Berckel, B.N.M. Blennow, K. Van Buchem, M.A. Cavedo, E. Chen, K. Chipi, E. Cohen, A.D. Förster, S. Fortea, J. Frederiksen, K.S. Freund-Levi, Y. Gkatzima, O. Gordon, M.F. Grimmer, T. Hampel, H. Hausner, L. Hellwig, S. Herukka, S.-K. Johannsen, P. Klimkowicz-Mrowiec, A. Köhler, S. Koglin, N. Van Laere, K. De Leon, M. Lisetti, V. Maier, W. Marcusson, J. Meulenbroek, O. Møllergård, H.M. Morris, J.C. Nordlund, A. Novak, G.P. Paraskevas, G.P. Perera, G. Peters, O. Ramakers, I.H.G.B. Rami, L. Rodríguez-Rodríguez, E. Roe, C.M. Rot, U. Rüther, E. Santana, I. Schröder, J. Seo, S.W. Sorininen, H. Spiru, L. Stomrud, E. Struyfs, H. Teunissen, C.E. Vos, S.J.B. Van Waalwijk Van Doorn, L.J.C. Waldemar, G. Wallin, Å.K. Wiltfang, J. Zetterberg, H. Amyloid Biomarker Study Group

Subjects
mental disorders
Abstract

IMPORTANCE Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. OBJECTIVE To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017. MAIN OUTCOMES AND MEASURES Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype. RESULTS Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4%[95%CI, 0%-7%] at 72 years and 21% [95%CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3%[95%CI, -1%to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16%[95%CI, 12%-20%], P < .001) and low MMSE (mean difference, 14%[95%CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years. CONCLUSIONS AND RELEVANCE Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.

Published
2018

25. PS1372 B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY

Author

Popat, R., primary, Lendvai, N., additional, Trudel, S., additional, Voorhees, P.M., additional, Reeves, B., additional, Libby, E.N., additional, Richardson, P.G., additional, Jr, L.D. Anderson, additional, Sutherland, H.J., additional, Yong, K., additional, Hoos, A., additional, Gorczyca, M.M., additional, He, Z., additional, Jewell, R.C., additional, Dettman, E.J., additional, Rigat, F., additional, Gupta, I., additional, Bragulat, V., additional, Opalinska, J.B., additional, and Cohen, A.D., additional

Published
2019
Full Text
View/download PDF

27. 慢性荨麻疹和骨质疏松

Author

Shalom, G., primary, Kridin, K., additional, Babaev, M., additional, Magen, E., additional, Tiosano, S., additional, Dreiher, J., additional, Horev, A., additional, Khury, R., additional, Comaneshter, D., additional, Agmon‐Levin, N., additional, and Cohen, A.D., additional

Published
2019
Full Text
View/download PDF

28. Chronic urticaria and osteoporosis

Author

Shalom, G., primary, Kridin, K., additional, Babaev, M., additional, Magen, E., additional, Tiosano, S., additional, Dreiher, J., additional, Horev, A., additional, Khury, R., additional, Comaneshter, D., additional, Agmon‐Levin, N., additional, and Cohen, A.D., additional

Published
2019
Full Text
View/download PDF

31. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study.

Author

Tzur Bitan, D., Berzin, D., and Cohen, A.D.

Subjects
HIDRADENITIS suppurativa, SCHIZOPHRENIA, MENTAL illness, COHORT analysis, MEDICAL care
Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, debilitating, dermatological disease that causes substantial psychosocial impediments with increased suicidal risk. Yet data on psychiatric comorbidity in HS have not been sufficiently elucidated in population‐based studies. The current study sought to investigate the association between HS and schizophrenia, a major psychiatric disease, in a nationwide population‐based study in Israel. Methods: Data mining was performed on the database of Clalit Health Services (CHS), the largest managed healthcare company in Israel. Patients diagnosed with HS (n = 4191) were examined and compared to age‐ and sex‐matched controls (n = 20 941). The association between HS and schizophrenia was assessed via multivariate binary logistic regression, adjusting for demographic factors and smoking status. Results: The analysis revealed a tenfold increase in the prevalence of schizophrenia in HS patients compared to controls (1.4% and 0.4%, respectively, P < 0.001). In multivariate analysis, HS was found to be associated with schizophrenia (OR 1.44, 95% CI 1.01–2.07, P < 0.05). Conclusions: Hidradenitis suppurativa is associated with schizophrenia. Screening for severe mental illness during the assessment of patients with HS is of great importance, as comorbid psychiatric disorders may affect treatment outcomes. Linked Commentary: F. Poot. J Eur Acad Dermatol Venereol 2020; 34: 442–443. https://doi.org/10.1111/jdv.16260. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Treatment and clinical outcomes in anti‐p200 pemphigoid: a systematic review.

Author

Laufer Britva, R., Amber, K.T., Cohen, A.D., and Kridin, K.

Subjects
META-analysis, TREATMENT effectiveness, DISEASE progression, PREVENTIVE medicine
Abstract

Background: Current treatment paradigms in anti‐p200 pemphigoid rely on low levels of evidence, primarily originating from case reports and case series. Objective: To systematically review the utilized treatment modalities for anti‐p200 pemphigoid and to synthesize the available clinical outcomes of treated patients. Methods: We conducted a systematic review of the literature using Ovid‐Medline (1946–2018), Embase (1947–2018) and Web of Science (1900–2018) databases with a broad and inclusive search strategy along with a subsequent search of retrieved articles. All case reports and case series of patients with anti‐p200 pemphigoid were included. Results: Sixty‐eight eligible studies comprising 113 anti‐p200 pemphigoid patients with a mean age of 65.5 years were included in the qualitative synthesis. The clinical outcome of patients following treatment was reported for 91 (80.5%) patients, of whom 83 (91.2%) had achieved complete remission at least once. Complete remission on‐therapy was observed in 51 (56.0%) and complete remission off‐therapy in 12 (13.2%) patients. Thirty‐six (39.6%) patients had experienced at least one flare during the duration of follow‐up. A combination of systemic corticosteroids and adjuvant immunomodulatory agents was the leading therapeutic approach (63.0%) required for disease control. Systemic and topical corticosteroids as monotherapy were sufficient to control the disease in 19.6% and 13.0% of cases, respectively. Dapsone was the most commonly used (41.3%) adjuvant agent. The highest rates of complete remission were achieved in patients managed by systemic corticosteroids as monotherapy (100%) and in those managed by systemic corticosteroids with adjuvant agents (90.7%). Conversely, 45.5% of patients treated only by topical corticosteroids experienced at least one relapse during follow‐up. Conclusion: The vast majority of patients had reached a complete remission during the course of the disease, whereas a considerable proportion of patients experienced at least one relapse. A combination of systemic corticosteroids and adjuvant immunomodulatory agents was the most frequently utilized therapeutic approach. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. 化脓性汗腺炎研究的核心结果的全球共识:历史性共识会议I和II的更新

Author

Thorlacius, L., primary, Garg, A., additional, Ingram, J.R., additional, Villumsen, B., additional, Theut Rii, P., additional, Gottlieb, A.B., additional, Merola, J.F., additional, Dellavalle, R., additional, Ardon, C., additional, Baba, R., additional, Bechara, F.G., additional, Cohen, A.D., additional, Daham, N., additional, Davis, M., additional, Emtestam, L., additional, Fernández-Peñas, P., additional, Filippelli, M., additional, Gibbons, A., additional, Grant, T., additional, Guilbault, S., additional, Gulliver, S., additional, Harris, C, additional, Harvent, C., additional, Houston, K., additional, Kirby, J.S., additional, Matusiak, L., additional, Mehdizadeh, A., additional, Mojica, T., additional, Okun, M., additional, Orgill, D., additional, Pallack, L., additional, Parks-Miller, A., additional, Prens, E.P., additional, Randell, S., additional, Rogers, C., additional, Rosen, C.F., additional, Choon, S.E., additional, van der Zee, H.H., additional, Christensen, R., additional, and Jemec, G.B.E., additional

Published
2018
Full Text
View/download PDF

40. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II

Author

Thorlacius, L., primary, Garg, A., additional, Ingram, J.R., additional, Villumsen, B., additional, Theut Rii, P., additional, Gottlieb, A.B., additional, Merola, J.F., additional, Dellavalle, R., additional, Ardon, C., additional, Baba, R., additional, Bechara, F.G., additional, Cohen, A.D., additional, Daham, N., additional, Davis, M., additional, Emtestam, L., additional, Fernández-Peñas, P., additional, Filippelli, M., additional, Gibbons, A., additional, Grant, T., additional, Guilbault, S., additional, Gulliver, S., additional, Harris, C., additional, Harvent, C., additional, Houston, K., additional, Kirby, J.S., additional, Matusiak, L., additional, Mehdizadeh, A., additional, Mojica, T., additional, Okun, M., additional, Orgill, D., additional, Pallack, L., additional, Parks-Miller, A., additional, Prens, E.P., additional, Randell, S., additional, Rogers, C., additional, Rosen, C.F., additional, Choon, S.E., additional, van der Zee, H.H., additional, Christensen, R., additional, and Jemec, G.B.E., additional

Published
2018
Full Text
View/download PDF

43. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

Author

Cohen, A.D., primary, Wu, J.J., additional, Puig, L., additional, Chimenti, S., additional, Vender, R., additional, Rajagopalan, M., additional, Romiti, R., additional, de la Cruz, C., additional, Skov, L., additional, Zachariae, C., additional, Young, H.S., additional, Foley, P., additional, van der Walt, J.M., additional, Naldi, L., additional, Prens, E.P., additional, and Blauvelt, A., additional

Published
2017
Full Text
View/download PDF

44. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries

Author

Busard, C.I., primary, Cohen, A.D., additional, Wolf, P., additional, Gkalpakiotis, S., additional, Cazzaniga, S., additional, Stern, R.S., additional, Hutten, B.A., additional, Feldhamer, I., additional, Quehenberger, F., additional, Lichem, R., additional, Kojanova, M., additional, Adenubiova, E., additional, Addis, A., additional, Naldi, L., additional, and Spuls, P.I., additional

Published
2017
Full Text
View/download PDF

47. Hidradenitis suppurativa and sleep disorders: a population‐based study.

Author

Cohen, J.M., Kridin, K., Perez‐Chada, L.M., Merola, J.F., and Cohen, A.D.

Subjects
HIDRADENITIS suppurativa, SLEEP disorders, SLEEP apnea syndromes, PHYSICIANS
Abstract

The relationship between HS and OSA and nSD weakened in multivariate models, suggesting that other risk factors do contribute to OSA and nSD. HS is believed to induce a systemic pro-inflammatory state.4 We propose that OSA and nSD, which are also accompanied by systemic inflammatory states, may be triggered by the cytokine milieu of HS in susceptible individuals. A previous retrospective cohort study of 19 945 individuals with HS and 296 170 matched controls in the United States interrogated the incidence of OSA in HS patients and controls. [Extracted from the article]

Published
2021
Full Text
View/download PDF

49. Introducing global peat-specific temperature and pH calibrations based on brGDGT bacterial lipids

Author

Naafs, B.D.A., primary, Inglis, G.N., additional, Zheng, Y., additional, Amesbury, M.J., additional, Biester, H., additional, Bindler, R., additional, Blewett, J., additional, Burrows, M.A., additional, del Castillo Torres, D., additional, Chambers, F.M., additional, Cohen, A.D., additional, Evershed, R.P., additional, Feakins, S.J., additional, Gałka, M., additional, Gallego-Sala, A., additional, Gandois, L., additional, Gray, D.M., additional, Hatcher, P.G., additional, Honorio Coronado, E.N., additional, Hughes, P.D.M., additional, Huguet, A., additional, Könönen, M., additional, Laggoun-Défarge, F., additional, Lähteenoja, O., additional, Lamentowicz, M., additional, Marchant, R., additional, McClymont, E., additional, Pontevedra-Pombal, X., additional, Ponton, C., additional, Pourmand, A., additional, Rizzuti, A.M., additional, Rochefort, L., additional, Schellekens, J., additional, De Vleeschouwer, F., additional, and Pancost, R.D., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results